BETA-PRIME: A Phase 1/2, First in Human, Study to Evaluate the Safety and Tolerability of AdAPT-001 in Subjects with Refractory Solid Tumors
NCT #
NCT04673942
Condition(s)
Solid Tumor
Molecular Target(s)
Not Required
Drug Classification(s)
Oncolytic virus
Agents(s)
AdAPT-001
Phase(s)
I/II
Mechanism of Action
AdAPT-001 is an oncolytic adenovirus that expresses a TGF-β (beta) trap fusion protein
Purpose
- The effects of the study agent (good and bad)
- About the safety and tolerability of the study agent
- If research tests can be used in the future to predict who will benefit from AdAPT-001
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy, Small Molecule
KRAS
Solid Tumor
Yes
24-05
BG-68501 is a CDK2 Inhibitor
CDK2 Inhibitor, Molecular Targeted Therapy
CDK2
Solid Tumor
No
JIT-TSC-007
n/a
Molecular Targeted Therapy
TSC1, TSC2
Solid Tumor
No
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.